Ask AI
Frontline Management of Transplant Ineligible MM

CE

Frontline Management of Transplant-Ineligible Multiple Myeloma: Optimizing Therapy, Supportive Care, and Patient Outcomes

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 31, 2026

Expiration: January 30, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss frontline management of multiple myeloma (MM) in transplant-ineligible patients, emphasizing the role of frailty assessment, evidence supporting triplet and quadruplet therapies, supportive care strategies, and individualized treatment decisions to optimize outcomes.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with transplant-ineligible MM do you provide care for in a typical month?​

For those who practice in academic or community settings, please indicate your practice setting:

For patients receiving anti-CD38 antibodies, prophylaxis is mandatory in clinical practice for which of the following infections?

A 75-year-old man presents with fatigue, weight loss, new back pain, and controlled hypertension​. His hemoglobin is 9.5 g/dL​, serum creatinine is 1.3 mg/dL, serum M-protein is 3.8 g/dL​, 50% clonal plasma cells​, and Eastern Cooperative Oncology Group performance score is 1​.

Which would you recommend as most appropriate?​